Media and Communications

News

Corporate

Tuesday, January 20, 2015
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review

Positive Decision Requires Federal Circuit to Reconsider its Invalidity Ruling in the Case, Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. regarding Teva’s ‘808 Patent JERUSALEM--(BUSINESS WIRE)--Jan. 20, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for COPAXONE® (glatiramer acetate i Read More »

Tuesday, January 06, 2015
Teva Launches Generic Diovan® in the United States

JERUSALEM--(BUSINESS WIRE)--Jan. 6, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the Food and Drug Administration (FDA) approval and the launch of the generic equivalent to Diovan® (Valsartan) Tablets in the United States. Diovan® (Valsartan) Tablets, marketed by Novartis Pharmaceuticals, had annual sales of approximately $1.8 billion in the United States, according to IMS data as of October 2014. About Teva Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global ph Read More »

Tuesday, December 23, 2014
FDA Approves Teva’s GRANIX® (tbo-filgrastim) Injection for Self-Administration

New Administration Option Will Offer Patients More Treatment Flexibility JERUSALEM--(BUSINESS WIRE)--Dec. 23, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved GRANIX® (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe GRANIX for either in-office or at home use. GRANIX, a leukocyte growth f Read More »

Wednesday, December 10, 2014
Teva Announces Launch of First Generic Celebrex® Capsules in the United States

JERUSALEM--(BUSINESS WIRE)--Dec. 10, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the first FDA-approved generic equivalent to Celebrex® (Celecoxib) Capsules in the United States. Teva is offering 50, 100, 200, and 400 mg strengths of Celecoxib Capsules. “Teva is pleased to be the first to launch generic Celebrex®. The addition of Celecoxib Capsules to our US generics portfolio is further evidence of Teva’s commitment to bring affordable treatment solutions to patients,” said Siggi Olafsson, Read More »

Thursday, December 04, 2014
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)

MHRA and other EU Member States Issue Positive Assessment Report under the Decentralized Procedure for New, Three-Times-A-Week COPAXONE® 40 mg/ml Formulation     JERUSALEM--(BUSINESS WIRE)--Dec. 4, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week COPAXONE® (glatiramer acetate) 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis (RMS). The outcome follows a Positive Read More »

Monday, December 01, 2014
Teva to Host 2015 Business Outlook Conference Call and Webcast on December 11, 2014

JERUSALEM--(BUSINESS WIRE)--Dec. 1, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will host a conference call and live webcast on Thursday, December 11, 2014 at 8:00 a.m. EST to communicate its 2015 business outlook. A question & answer session will follow. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 1-888-771-4371; for Israel 1809-212-582; for a list of other international telephone numbers, CLIC Read More »

Tuesday, November 18, 2014
Teva Launches Liquid Formulation of TREANDA® (bendamustine HCI) Injection in U.S.

New Formulation Eliminates Need for Reconstitution JERUSALEM--(BUSINESS WIRE)--Nov. 18, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the commercial availability of a liquid formulation of TREANDA® (bendamustine HCI) Injection. This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the required dose of medicine to the infusion bag and administering to a patient. By eliminating the need for reconstitution, preparation time for healthcare professionals is reduced. “TREANDA® continues to play a valuable ro Read More »

Friday, September 12, 2014
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Sep. 12, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in t Read More »

Friday, September 12, 2014
Teva Presents Gene Expression Analysis at Joint Actrims-Ectrims Meeting Demonstrating Copaxone® (Glatiramer Acetate Injection) Has a Complex Profile

Data Explore Differences between Gene Expression Profiles of Teva’s COPAXONE® and Other Glatiramer Acetate Products JERUSALEM--(BUSINESS WIRE)--Sep. 12, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that new scientific data presented at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting reveals differences in the gene expression profile between COPAXONE® (glatiramer acetate injection) and other glatiramer acetate products. In this research, a human monocyte cell line was stimulated by either Read More »

Thursday, September 11, 2014
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg

JERUSALEM--(BUSINESS WIRE)--Sep. 11, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced new data from the open-label Phase IIIb GLatiramer Acetate low frequenCy safety and patIent ExpeRience (GLACIER) study, comparing the safety and tolerability of three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg to daily COPAXONE® 20 mg in patients with relapsing-remitting multiple sclerosis (RRMS). During a platform presentation this week, the results from the GLACIER study were shared at the MS Boston 201 Read More »

​​​